Building Trust in Rare Disease PSPs
- Life Sciences
- Experience
The MERGE team shares four key fundamentals essential for creating effective Patient Support Programs (PSPs) for rare disease communities
August 7, 2024
The MERGE team shares four key fundamentals essential for creating effective Patient Support Programs (PSPs) for rare disease communities
August 7, 2024
The development of Patient Support Programs (PSPs) for niche populations afflicted by rare diseases requires special considerations. These programs play a pivotal role in enhancing the quality of life for patients and their caregivers, and their design must reflect a deep understanding of the specific needs and challenges faced by these communities. Below, MERGE explores key fundamentals vital to creating effective PSPs: support, partnership and representation, transparency, and commitment.
Support: Listening and Understanding
Effective PSPs are built on a foundation of empathy and active listening. By engaging in meaningful dialogue, companies can truly understand the unmet needs of the community and seek to effectively solve those needs. They can also better understand the role of their therapeutic offering and how it may contribute to an individual’s quality of life. Listening to the community’s feedback allows companies to adapt their offerings to better meet the needs of those they aim to support. This approach ensures that the program is holistically relevant and meaningful in the real world.
Partnership and Representation: Building Authentic Relationships
To foster genuine connections with rare disease communities, it is crucial to activate and build partnerships with existing communities and advocacy groups, strong rooting in mutual trust and benefit. There are several elements critical to setting a strong foundation for a long-lasting partnership, which include furthering thoughtful and accurate disease education, supporting research and resources that drive the science forward, and fostering strong connections across stakeholders. Representing real patients and caregivers in communications adds a layer of authenticity and emotional connection that resonates deeply with the community, especially within rare diseases, where amplifying the patient/caregiver voice is so important. Authentic representation strengthens the credibility of the PSP and shows a commitment to understanding and addressing the unique challenges faced by patients and caregivers.
Transparency: Clearly Communicate and Demonstrate Intent
The cornerstone of any successful PSP is transparency. Trust must be established through clear, straightforward communication that articulates the brand’s vision and commitment to rare disease communities. It is essential to provide information that not only articulates product intent but also demonstrates brand integrity. Crafting messaging that stakes the company’s dedication to the case and community balanced with clear actions that demonstrate their dedication are both equally important. Consider trust theory in this context:
Ability: How effective are you?
Integrity: Do you say what you are going to do?
Benevolence: Do you have your customers’ best interests in mind?
By offering transparent, truthful insights, and demonstrating action behind the bigger cause, companies can start to build a foundation of trust that encourages patient participation and loyalty.
Commitment: Advocating Beyond the Product
A strong sense of commitment to the community is vital. It’s important to convey that the support extends beyond a single product to encompass the company’s broader efforts. This includes raising awareness, advocating for better treatments, and striving for care in a manner that feels holistic. Demonstrating the organization’s ongoing commitment to the rare disease community fosters long-term trust and loyalty. Patients need to see that the organization is an ally in their journey, advocating passionately for their well-being.
Serena Mistry Faria, MERGE SVP and Group Client Service Leader, contributed to this article.
